Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated:
March 6, 2026
Status:
Under consideration for negotiation
Manufacturer:
Apotex Inc.
Indication:
In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
Last updated:
February 26, 2026
Status:
Under consideration for negotiation
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Cardiomyopathy due to transthyretin-mediated amyloidosis
Last updated:
February 26, 2026
Status:
Active negotiation
Manufacturer:
LEO Pharma Inc.
Indication:
Chronic hand eczema
Last updated:
February 25, 2026
Status:
Active negotiation
Manufacturer:
Sanofi Genzyme Canada
Indication:
In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
Last updated:
February 20, 2026
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.
Last updated:
February 19, 2026
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Multiple Sclerosis, Relapsing-Remitting
Last updated:
February 12, 2026
Status:
Active negotiation
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.
Last updated:
February 11, 2026
Status:
Active negotiation
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer
Last updated:
February 11, 2026
Status:
Active negotiation
Manufacturer:
Ferring Canada Inc.
Indication:
Clostridioides difficile infection, prevention
Last updated:
February 11, 2026